$NVCR

Hung David sold $46K of NVCR

Hung David sold 2,945 shares of NovoCure Ltd (NVCR) at $15.77 on 2026-06-02.

Original reporting
SEC EDGAR · Hung David
Published Jun 3, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NVCR
Neutral
medium confidence
Mentioned
$NVCR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVCRNeutralLow
01

Why it matters

The primary tradable element is sentiment/positioning around NVCR following the disclosed sale; absent any new company fundamentals, impact is likely modest.

02

Market read

Traders may briefly reassess NVCR sentiment due to insider selling, but no new operating/financial catalyst is provided.

03

What to watch

Form 4 timing and the absence/presence of a 10b5-1 plan can be misread; size (2,945 shares) is relatively small versus typical institutional float, limiting signal strength.

Relevance 6/10Novelty 6/10Timing: after-hours/next-session read-through from today’s SEC Form 4 filing

Background

The article is an SEC EDGAR Form 4 disclosure of an insider transaction (director Hung David) for NovoCure Ltd.

Company-level read

Ticker impact

$NVCRNeutralMedium confidence
Context

NovoCure director Hung David sold 2,945 shares in an open-market transaction, disclosing a direct insider ownership change.

Expected impact

Likely limited/short-lived impact; watch for follow-on insider activity or broader news.

Evidence & confidence

The filing is a Form 4 insider sale with disclosed price and size; no 10b5-1 plan is indicated, but there is no accompanying company-specific operational or financial update.

Market effects

Minimal; this is company-specific insider activity without sector-wide information.

None indicated.

None indicated.

Counterpoint

A single director sale (even without a stated 10b5-1 plan) may reflect diversification or personal liquidity needs and may not signal deteriorating fundamentals.

Key entities

  • NovoCure Ltd

    Subject of the insider transaction disclosure (NVCR).

  • Hung David

    Director who sold shares via an open-market sale disclosed on Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVCRLowAI 8/10

Novocure partners with Verastem on pancreatic cancer trial

Novocure (NVCR) and Verastem Oncology (VSTM) partner to test Tumor Treating Fields therapy with VS-7375 for pancreatic cancer. Trial to start in 2027, focusing on safety and tolerability in 25 patients. Novocure will fund and manage the trial, while Verastem supplies the drug. The treatment aims to combine chemotherapy, VS-7375, and Tumor Treating Fields. Pancreatic cancer has a low survival rate and limited treatment options.

$NVCRLowAI 8/10

A planned trial will test electric-field therapy with chemotherapy and an experimental drug.

Novocure (NVCR) and Verastem Oncology plan a clinical trial to evaluate Tumor Treating Fields (TTFields) therapy with chemotherapy and Verastem’s experimental drug VS-7375 for locally advanced pancreatic cancer. The trial, expected to start in 2027, will assess safety and preliminary efficacy in about 25 patients. Novocure will manage and fund the trial, while Verastem will supply the drug. Both companies believe the combination could offer a new treatment approach for this challenging cancer.

$NVCRHighAI 9/10

Novocure’s Optune Pax approved in Japan for unresectable locally advanced pancreatic cancer

Novocure received approval from Japan's MHLW for Optune Pax to treat unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. The approval follows Phase 3 PANOVA-3 trial results showing improved median overall survival and delayed pain progression. The safety profile included expected skin events. According to the company, no new systemic safety signals were observed.

$NVCRHighAI 9/10

NovoCure Ltd (NVCR): Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

NovoCure Ltd (NVCR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Op